Management of PFO in Paradoxical Embolic Stroke with Hemorrhagic Conversion: a Case Report

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Oct 9

PMID 39380634

Authors

Michael Sabina

Aqeel Khanani

Joshua Tsai

Amanda Rigdon

Joseph Massaro

Affiliations

Soon will be listed here.

Abstract

A paradoxical embolism is defined as a venous thrombus that crosses through a heart defect, into the systemic circulation, usually through a patent foramen ovale. Treatment varies between closure of patent foramen ovale vs. medical management based on a variety of individual risk factors and the cardiac defect's characteristics. We describe a case of paradoxical stroke complicated by hemorrhagic conversion, ultimately requiring an IVC filter.

References

Mazya M, Egido J, Ford G, Lees K, Mikulik R, Toni D . Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012; 43(6):1524-31. DOI: 10.1161/STROKEAHA.111.644815. View

Robbins N, Swanson R . Opposing effects of glucose on stroke and reperfusion injury: acidosis, oxidative stress, and energy metabolism. Stroke. 2014; 45(6):1881-6. PMC: 4102697. DOI: 10.1161/STROKEAHA.114.004889. View

Zhang X, Cao X, Xu X, Li A, Xu Y . Correlation between the -1562C/T polymorphism in the matrix metalloproteinase-9 gene and hemorrhagic transformation of ischemic stroke. Exp Ther Med. 2015; 9(3):1043-1047. PMC: 4316928. DOI: 10.3892/etm.2015.2186. View

Elgendy A, Saver J, Amin Z, Boudoulas K, Carroll J, Elgendy I . Proposal for Updated Nomenclature and Classification of Potential Causative Mechanism in Patent Foramen Ovale-Associated Stroke. JAMA Neurol. 2020; 77(7):878-886. DOI: 10.1001/jamaneurol.2020.0458. View

Saver J, Mattle H, Thaler D . Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke: A Topical Review. Stroke. 2018; 49(6):1541-1548. DOI: 10.1161/STROKEAHA.117.018153. View

Hart R, Diener H, Coutts S, Easton J, Granger C, ODonnell M . Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014; 13(4):429-38. DOI: 10.1016/S1474-4422(13)70310-7. View

Mas J, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L . Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017; 377(11):1011-1021. DOI: 10.1056/NEJMoa1705915. View

Yeo L, Paliwal P, Teoh H, Seet R, Chan B, Liang S . Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke. JAMA Neurol. 2013; 70(3):353-8. DOI: 10.1001/2013.jamaneurol.547. View

Furlan A, Reisman M, Massaro J, Mauri L, Adams H, Albers G . Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012; 366(11):991-9. DOI: 10.1056/NEJMoa1009639. View

10.

Hallevi H, Albright K, Martin-Schild S, Barreto A, Savitz S, Escobar M . Anticoagulation after cardioembolic stroke: to bridge or not to bridge?. Arch Neurol. 2008; 65(9):1169-73. PMC: 2678170. DOI: 10.1001/archneur.65.9.noc70105. View

11.

Saver J, Carroll J, Thaler D, Smalling R, MacDonald L, Marks D . Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017; 377(11):1022-1032. DOI: 10.1056/NEJMoa1610057. View

12.

Meier B, Kalesan B, Mattle H, Khattab A, Hildick-Smith D, Dudek D . Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013; 368(12):1083-91. DOI: 10.1056/NEJMoa1211716. View

13.

Kent D, Ruthazer R, Weimar C, Mas J, Serena J, Homma S . An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013; 81(7):619-25. PMC: 3775694. DOI: 10.1212/WNL.0b013e3182a08d59. View

14.

Selim M, Fink J, Kumar S, Caplan L, Horkan C, Chen Y . Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002; 33(8):2047-52. DOI: 10.1161/01.str.0000023577.65990.4e. View

15.

Farb A, Ibrahim N, Zuckerman B . Patent Foramen Ovale after Cryptogenic Stroke - Assessing the Evidence for Closure. N Engl J Med. 2017; 377(11):1006-1009. DOI: 10.1056/NEJMp1700218. View

16.

Lee P, Song J, Kim J, Heo R, Lee S, Kim D . Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018; 71(20):2335-2342. DOI: 10.1016/j.jacc.2018.02.046. View

17.

Johnston K, Bruno A, Pauls Q, Hall C, Barrett K, Barsan W . Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019; 322(4):326-335. PMC: 6652154. DOI: 10.1001/jama.2019.9346. View

18.

Farjat-Pasos J, Chamorro A, Lanthier S, Robichaud M, Mengi S, Houde C . Cerebrovascular Events in Older Patients With Patent Foramen Ovale: Current Status and Future Perspectives. J Stroke. 2023; 25(3):338-349. PMC: 10574307. DOI: 10.5853/jos.2023.01599. View